FindTrial
Sign In

Ozempic®

DRUG6 trials

Sponsors

Novo Nordisk A/S, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., John Bauer, Shandong New Time Pharmaceutical Co., LTD

Conditions

Cardiovascular Disease Risk FactorDiabetes Mellitus, Type 2Obese AdolescentsObesity and OverweightType 2 DiabetesType 2 Diabetes (T2DM)Type 2 Diabetes MellitusWeight Loss

Phase 1

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
CompletedNCT06634927
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes
Start: 2024-09-22End: 2025-02-12Updated: 2025-08-01

Phase 3

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
CompletedNCT06161844
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Type 2 Diabetes Mellitus
Start: 2024-02-23End: 2025-05-14Updated: 2025-07-11
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
CompletedNCT06739044
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes
Start: 2023-09-20End: 2025-02-21Updated: 2025-07-28
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
Not yet recruitingNCT07046273
Shandong New Time Pharmaceutical Co., LTDType 2 Diabetes (T2DM)
Start: 2025-08-01End: 2029-02-01Target: 496Updated: 2025-07-01

Unknown Phase

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
CompletedNCT04572165
Novo Nordisk A/SDiabetes Mellitus, Type 2
Start: 2021-01-26End: 2025-11-25Updated: 2026-06-11
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
RecruitingNCT06967389
John BauerCardiovascular Disease Risk Factor, Obese Adolescents, Obesity and Overweight +2
Start: 2025-06-12End: 2028-07-01Target: 50Updated: 2026-07-21

Related Papers

839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial
Diabetes2025-06-13